Results 201 to 210 of about 11,476 (293)

A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP‐1 Agonists in the United Kingdom

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We previously showed that FreeStyle Libre (FSL) real‐time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self‐monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT‐2 inhibitor and ...
Sneha T. Amritlal   +15 more
wiley   +1 more source

Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the real‐world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like‐peptide‐1 receptor agonist (GLP‐1 RA)‐naïve individuals (i.e., no GLP‐1 RA prescription during the 12‐month pre‐index period) and GLP‐1 RA‐experienced ...
Chanadda Chinthammit   +6 more
wiley   +1 more source

Beyond Drugs or Surgery: Precision and Equity in Obesity Care

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Ron T. Varghese   +4 more
wiley   +1 more source

A Comparative Analysis Between Original and Updated Glucose Management Indicator and Glycated Haemoglobin Across Continuous Glucose Monitoring Sensors in Type 1 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The continuous glucose monitoring (CGM)‐derived glucose management indicator (GMI) is used for estimating glycated haemoglobin (HbA1c). This study assessed agreement between GMI—calculated using both original and updated (uGMI) models—and laboratory‐measured HbA1c across Dexcom, MiniMed and Abbott sensors. Materials and Methods Real‐world
Lavanta Farouk   +10 more
wiley   +1 more source

Differences in the Glucose Management Indicator Between Continuous Glucose Monitoring Systems

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim The glucose management indicator (GMI) estimates HbA1c from continuous glucose monitoring (CGM)‐derived mean glucose. We assessed whether this relationship differs between contemporary CGM systems. Materials and Methods In this observational study, mean sensor glucose was derived from 2 months of CGM data preceding HbA1c measurement in ...
Katrine Bovién Gørlitz   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy